PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing.
The round was led by Vida Ventures with participation from current investors.
As part of the round, Helen S. Kim, Managing Director at Vida Ventures, will join PACT Pharma’s Board of Directors.
The company’s technology is designed to individually program tumor-exclusive targeting into each patient’s own immune system cells to eradicate their own cancer.
Pact is also backed by GV (formerly Google Ventures), Canaan, Casdin Capital, Droia, Foresite Capital, Invus Opportunities, Pontifax and Wu Capital, AbbVie Ventures and Taiho Ventures. | To read full story, visit https://startuparound.com/read/1578913209.007136/PACT-Pharma-Secures-$75M-in-Series-C-Financing?ref=audio_experience